CEL-SCI’s Multikine Impresses with Breakthrough Data at ESMO 2024: What It Means for the Stock and Potential Buyout Opportunities
CEL-SCI Corporation (NYSE American: CVM) made headlines at the European Society for Medical Oncology (ESMO) 2024 Congress by presenting new...
Read more